Fidelity Investments’s Ovid Therapeutics OVID Stock Holding History

Fidelity Investments’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$93.5K	Sell	42,138 -1,836	-4%	-$3.28K	﹤0.01%	3817
2025 Q4	$71.7K	Sell	43,974 -3,013	-6%	-$4.64K	﹤0.01%	3922
2025 Q3	$61.1K	Sell	46,987 -1	-0%	-$1	﹤0.01%	3883
2025 Q2	$15.5K	Buy	46,988 +16,091	+52%	+$4.85K	﹤0.01%	4381
2025 Q1	$9.64K	Sell	30,897 -4,019	-12%	-$2.47K	﹤0.01%	4512
2024 Q4	$32.6K	Sell	34,916 -15,309	-30%	-$17.1K	﹤0.01%	4029
2024 Q3	$59.3K	Buy	50,225 +47,723	+1,907%	+$49.9K	﹤0.01%	3711
2024 Q2	$1.93K	Sell	2,502 -83,705	-97%	-$233K	﹤0.01%	4729
2024 Q1	$263K	Buy	86,207 +982	+1%	+$3.29K	﹤0.01%	2938
2023 Q4	$274K	Sell	85,225 -6,281	-7%	-$21.5K	﹤0.01%	2859
2023 Q3	$351K	Sell	91,506 -19	-0%	-$68	﹤0.01%	2723
2023 Q2	$300K	Buy	91,525 +125	+0.1%	+$424	﹤0.01%	2823
2023 Q1	$236K	Hold	91,400	–	–	﹤0.01%	2923
2022 Q4	$170K	Sell	91,400 -1,257	-1%	-$2.14K	﹤0.01%	3050
2022 Q3	$170K	Sell	92,657 -2,000	-2%	-$4.18K	﹤0.01%	3095
2022 Q2	$204K	Buy	94,657 +444	+0.5%	+$1.07K	﹤0.01%	3123
2022 Q1	$296K	Buy	94,213 +93,213	+9,321%	+$293K	﹤0.01%	3147
2021 Q4	$3K	Hold	1,000	–	–	﹤0.01%	3941
2021 Q3	$3K	Buy	+1,000	New	+$3.65K	﹤0.01%	3918
2020 Q4	–	Sell	-1,708,646	Closed	-$9.81M	–	4168
2020 Q3	$9.81M	Sell	1,708,646 -72,569	-4%	-$486K	﹤0.01%	1841
2020 Q2	$13.1M	Sell	1,781,215 -303,685	-15%	-$1.42M	﹤0.01%	1713
2020 Q1	$6.21M	Hold	2,084,900	–	–	﹤0.01%	1857
2019 Q4	$8.65M	Buy	+2,084,900	New	+$6.58M	﹤0.01%	1896
2018 Q4	–	Sell	-1,015,805	Closed	-$5.76M	–	3961
2018 Q3	$5.76M	Sell	1,015,805 -298,019	-23%	-$2.26M	﹤0.01%	2108
2018 Q2	$10.2M	Sell	1,313,824 -71,242	-5%	-$612K	﹤0.01%	1936
2018 Q1	$9.79M	Sell	1,385,066 -88,807	-6%	-$718K	﹤0.01%	1966
2017 Q4	$14.5M	Sell	1,473,873 -171,172	-10%	-$1.57M	﹤0.01%	1832
2017 Q3	$13.8M	Sell	1,645,045 -169,802	-9%	-$1.41M	﹤0.01%	1830
2017 Q2	$18.3M	Buy	+1,814,847	New	+$23.7M	﹤0.01%	1715

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments's OVID Position: Q1 2026 in Review

Fidelity Investments reduced its Ovid Therapeutics (OVID) stake by 4.2% in Q1 2026, selling an estimated $3.28K and leaving 42,138 shares worth $93.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

Fidelity Investments first reported a position in OVID in Q2 2017 and has held it in 29 quarters since. The position peaked at $18.3M in Q2 2017. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Fidelity Investments held 42,138 shares of Ovid Therapeutics worth $93.5K as of Q1 2026.
Fidelity Investments sold 1,836 Ovid Therapeutics shares in Q1 2026, an estimated $3.28K.
Ovid Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3817 holding.
Fidelity Investments first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 29 quarters since.
Fidelity Investments's Ovid Therapeutics position peaked at $18.3M in Q2 2017.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.